Dihydrocapsaicin down-regulates apoM expression through inhibiting Foxa2 expression and enhancing LXRα expression in HepG2 cells

Lipids in Health and Disease

Qian Wang²  Lei Zheng²  Yan-Hua Sha²  Ji-Juan Gao²  Yan-Chao Wang²  Shao-Guo Wu²  Xin Ma¹  Ya-Rong Hu²  Shu-Fen Li²  Yan-Wei Hu²  Jia-Yi Zhao² 

[1] Department of Anesthesiology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China;Laboratory Medicine Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China

关键词: LXRα;    Foxa2;    ApoM;    DHC;   

Others  :  805438
DOI  :  10.1186/1476-511X-13-50

 received in 2013-12-12, accepted in 2014-03-13,  发布年份 2014

【 摘 要 】

Background

Apolipoprotein M (apoM), as a novel apolipoprotein which is mainly expressed in liver and kidney tissues, is associated with development and progression of atherosclerosis and diabetes. Our group have recently shown that Dihydrocapsaicin(DHC)can significantly decrease atherosclerotic plaque formation in apoE−/− mice. However, the effect and possible mechanism of DHC on apoM expression remain unclear.

Methods

HepG2 cells were treated with 0 μM, 25 μM, 50 μM and 100 μM DHC for 24 h or were treated with 100 μM DHC for 0, 6, 12, and 24 h, respectively. The mRNA levels and protein levels were measured by real-time quantitative PCR and western blot analysis, respectively.

Results

We found that DHC markedly decreased expression of apoM at both mRNA and protein level in HepG2 cells in a dose-dependent and time-dependent manner. Expression of Foxa2 was decreased while expression of LXRα was increased by DHC treatment in HepG2 cells. In addittion, overexpression of Foxa2 markedly compensated the inhibition effect induced by DHC on apoM expression. LXRα small interfering RNA significantly abolished the inhibition effect which induced by DHC on apoM expression. The liver of C57BL/6 mice treated with DHC had significantly lower expression of apoM. Furthermore, the liver had lower expression of Foxa2 while had higher expression of LXRα.

Conclusions

DHC could down-regulate apoM expression through inhibiting Foxa2 expression and enhancing LXRα expression in HepG2 cells.

【 授权许可】

   
2014 Zhao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Hu YW, Ma X, Huang JL, Mao XR, Yang JY, Zhao JY, Li SF, Qiu YR, Yang J, Zheng L, Wang Q: Dihydrocapsaicin attenuates plaque formation through a PPARgamma/LXRalpha pathway in apoE mice fed a high-fat/high-cholesterol diet. PLoS One 2013, 8(6):e66876.
• [2]Oh SH, Kim YS, Lim SC, Hou YF, Chang IY, You HJ: Dihydrocapsaicin (DHC), a saturated structural analog of capsaicin, induces autophagy in human cancer cells in a catalase-regulated manner. Autophagy 2008, 4(8):1009-1019.
• [3]Domotor A, Szolcsanyi J, Mozsik G: Capsaicin and glucose absorption and utilization in healthy human subjects. Eur J Pharmacol 2006, 534(1–3):280-283.
• [4]Lim K, Yoshioka M, Kikuzato S, Kiyonaga A, Tanaka H, Shindo M, Suzuki M: Dietary red pepper ingestion increases carbohydrate oxidation at rest and during exercise in runners. Med Sci Sports Exerc 1997, 29(3):355-361.
• [5]Inoue N, Matsunaga Y, Satoh H, Takahashi M: Enhanced energy expenditure and fat oxidation in humans with high BMI scores by the ingestion of novel and non-pungent capsaicin analogues (capsinoids). Biosci Biotechnol Biochem 2007, 71(2):380-389.
• [6]Ahuja KD, Ball MJ: Effects of daily ingestion of chilli on serum lipoprotein oxidation in adult men and women. Br J Nutr 2006, 96(2):239-242.
• [7]Ahuja KD, Kunde DA, Ball MJ, Geraghty DP: Effects of capsaicin, dihydrocapsaicin, and curcumin on copper-induced oxidation of human serum lipids. J Agric Food Chem 2006, 54(17):6436-6439.
• [8]Kempaiah RK, Manjunatha H, Srinivasan K: Protective effect of dietary capsaicin on induced oxidation of low-density lipoprotein in rats. Mol Cell Biochem 2005, 275(1–2):7-13.
• [9]Cordell GA, Araujo OE: Capsaicin: identification, nomenclature, and pharmacotherapy. Ann Pharmacother 1993, 27(3):330-336.
• [10]Ahuja KD, Robertson IK, Geraghty DP, Ball MJ: Effects of chili consumption on postprandial glucose, insulin, and energy metabolism. Am J Clin Nutr 2006, 84(1):63-69.
• [11]Adams MJ, Ahuja KD, Geraghty DP: Effect of capsaicin and dihydrocapsaicin on in vitro blood coagulation and platelet aggregation. Thromb Res 2009, 124(6):721-723.
• [12]Xu N, Dahlback B: A novel human apolipoprotein (apoM). J Biol Chem 1999, 274(44):31286-31290.
• [13]Duan J, Dahlback B, Villoutreix BO: Proposed lipocalin fold for apolipoprotein M based on bioinformatics and site-directed mutagenesis. Febs Lett 2001, 499(1–2):127-132.
• [14]Sevvana M, Ahnstrom J, Egerer-Sieber C, Lange HA, Dahlback B, Muller YA: Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M. J Mol Biol 2009, 393(4):920-936.
• [15]Luo G, Zhang X, Nilsson-Ehle P, Xu N: Apolipoprotein M. Lipids Health Dis 2004, 3:21. BioMed Central Full Text
• [16]Zhang XY, Dong X, Zheng L, Luo GH, Liu YH, Ekstrom U, Nilsson-Ehle P, Ye Q, Xu N: Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. Acta Histochem 2003, 105(1):67-72.
• [17]Zhang XY, Jiao GQ, Hurtig M, Dong X, Zheng L, Luo GH, Nilsson-Ehle P, Ye Q, Xu N: Expression pattern of apolipoprotein M during mouse and human embryogenesis. Acta Histochem 2004, 106(2):123-128.
• [18]Wolfrum C, Poy MN, Stoffel M: Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 2005, 11(4):418-422.
• [19]Plomgaard P, Dullaart RP, de Vries R, Groen AK, Dahlback B, Nielsen LB: Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects. J Intern Med 2009, 266(3):258-267.
• [20]Zhang X, Jiang B, Luo G, Nilsson-Ehle P, Xu N: Hyperglycemia down-regulates apolipoprotein M expression in vivo and in vitro. Biochim Biophys Acta 2007, 1771(7):879-882.
• [21]Sund NJ, Vatamaniuk MZ, Casey M, Ang SL, Magnuson MA, Stoffers DA, Matschinsky FM, Kaestner KH: Tissue-specific deletion of Foxa2 in pancreatic beta cells results in hyperinsulinemic hypoglycemia. Genes Dev 2001, 15(13):1706-1715.
• [22]Lee CS, Friedman JR, Fulmer JT, Kaestner KH: The initiation of liver development is dependent on foxa transcription factors. Nature 2005, 435(7044):944-947.
• [23]Wolfrum C, Asilmaz E, Luca E, Friedman JM, Stoffel M: Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 2004, 432(7020):1027-1032.
• [24]Wolfrum C, Howell JJ, Ndungo E, Stoffel M: Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M. J Biol Chem 2008, 283(24):16940-16949.
• [25]Pettersson AM, Stenson BM, Lorente-Cebrian S, Andersson DP, Mejhert N, Kratzel J, Astrom G, Dahlman I, Chibalin AV, Arner P, Laurencikiene J: LXR is a negative regulator of glucose uptake in human adipocytes. Diabetologia 2013, 56(9):2044-2054.
• [26]Zelcer N, Tontonoz P: Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006, 116(3):607-614.
• [27]Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ: Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294(5548):1866-1870.
• [28]Zhang X, Zhu Z, Luo G, Zheng L, Nilsson-Ehle P, Xu N: Liver X receptor agonist downregulates hepatic apoM expression in vivo and in vitro. Biochem Biophys Res Commun 2008, 371(1):114-117.
• [29]Peng J, Li YJ: The vanilloid receptor TRPV1: role in cardiovascular and gastrointestinal protection. Eur J Pharmacol 2010, 627(1–3):1-7.
• [30]Choi SE, Kim TH, Yi SA, Hwang YC, Hwang WS, Choe SJ, Han SJ, Kim HJ, Kim DJ, Kang Y, Lee KW: Capsaicin attenuates palmitate-induced expression of macrophage inflammatory protein 1 and interleukin 8 by increasing palmitate oxidation and reducing c-Jun activation in THP-1 (human acute monocytic leukemia cell) cells. Nutr Res 2011, 31(6):468-478.
• [31]Liu Y, Nair MG: Capsaicinoids in the hottest pepper Bhut Jolokia and its antioxidant and antiinflammatory activities. Nat Prod Commun 2010, 5(1):91-94.
• [32]Christoffersen C, Jauhiainen M, Moser M, Porse B, Ehnholm C, Boesl M, Dahlback B, Nielsen LB: Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem 2008, 283(4):1839-1847.
• [33]Nielsen LB, Christoffersen C, Ahnstrom J, Dahlback B: ApoM: gene regulation and effects on HDL metabolism. Trends Endocrinol Metab 2009, 20(2):66-71.
• [34]Dullaart RP, Plomgaard P, de Vries R, Dahlback B, Nielsen LB: Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness. Clin Chim Acta 2009, 406(1–2):129-133.
• [35]Hu YW, Zheng L, Wang Q: Characteristics of apolipoprotein M and its relation to atherosclerosis and diabetes. Biochim Biophys Acta 2010, 1801(2):100-105.
• [36]Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH, Dahlback B: Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 2006, 47(8):1833-1843.
• [37]Feingold KR, Shigenaga JK, Chui LG, Moser A, Khovidhunkit W, Grunfeld C: Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis 2008, 199(1):19-26.
• [38]Huang XS, Zhao SP, Hu M, Luo YP: Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation. Med Hypotheses 2007, 69(1):136-140.
• [39]Wolfrum C, Besser D, Luca E, Stoffel M: Insulin regulates the activity of forkhead transcription factor Hnf-3beta/Foxa-2 by Akt-mediated phosphorylation and nuclear/cytosolic localization. Proc Natl Acad Sci U S A 2003, 100(20):11624-11629.
• [40]Calkin AC, Tontonoz P: Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol 2012, 13(4):213-224.